<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JCT</journal-id><journal-title-group><journal-title>Journal of Cancer Therapy</journal-title></journal-title-group><issn pub-type="epub">2151-1934</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jct.2018.97047</article-id><article-id pub-id-type="publisher-id">JCT-85896</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  The Efficacy of Podophyllin Cautery Added to Surgical Excision for Eradication of Vulvar Condylomata Accuminata; Randomized Controlled Trial
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hussein</surname><given-names>O. Soliman</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yossra</surname><given-names>Lashin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Gynecology and Obstetrics, Faculty of Medicine, Cairo University, Giza, Egypt</addr-line></aff><aff id="aff1"><addr-line>Department of Surgical Oncology, National Cancer Institute, Cairo University, Giza, Egypt</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>soliman@daad-alumni.de(HOS)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>07</month><year>2018</year></pub-date><volume>09</volume><issue>07</issue><fpage>559</fpage><lpage>567</lpage><history><date date-type="received"><day>13,</day>	<month>June</month>	<year>2018</year></date><date date-type="rev-recd"><day>7,</day>	<month>July</month>	<year>2018</year>	</date><date date-type="accepted"><day>10,</day>	<month>July</month>	<year>2018</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Context: 
  Condyloma
   
  acuminatum is a common morbidity caused by human papillomavirus infection. <b>Objective:</b> To compare the recurrence rate after surgical excision with or without podophyllin cautery. <b>Design, Setting, Participants: </b>Sixty women were enrolled
   
  in a study that was conducted in Cairo from Jan-2017 to Mar-2018. <b>Interventions:</b>
  <b> </b>
  All women
   
  received the same preparations. After randomization; in the study group
   
  (N = 30), podophyllin cautery was added to surgical removal in the follow-up period. In the control group (N = 30), only surgical removal was
   
  used. <b>Main Outcome Measure:</b>
  <b> </b>
  The
   
  main
   
  outcome measure was the estimation of the recurrence of the lesion during the follow-up period. The secondary outcome measures were the incidence of adverse events. <b>Results:</b> Both groups were comparable (p-value &gt;
   
  0.05) with regard to the age and BMI. Recurrence was significantly lower (P =
   
  0.001) in the
   
  study
   
  group
   
  than
   
  the control group. In the study group, five cases (17.2%) have recurrence whereas, in the control group, 18 (60.0%) had suffered recurrence. The ARR was 42.8% (CI 95%: 18
  % 
  -
   
  60.9%) with RR of 0.29 (CI 95%: 0.12%
   
  -
   
  0.67%) and NNT2 (CI 95%: 6%
   
  -
   
  2%). During the follow-up period, 19 cases (65.5%) of the study group experienced pain versus only eight cases (26.7%) in the control group (p = 0.003). However, the development of scars was less in the study group 7 (24.1%) than in the control group 19 (63.3%), (p = 0.002). <b>Conclusion:</b> Podophyllin cautery, when added to surgical removal, is effective in decreasing the incidence recurrence in cases with condylomata
   
  acuminata.
 
</p></abstract><kwd-group><kwd>Condyloma Acuminatum</kwd><kwd> Recurrence</kwd><kwd> Adverse Events</kwd><kwd> Podophyllin Cautery</kwd><kwd> Surgical Excision</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The anogenital wart, condyloma acuminatum (CA) is caused by human papillomavirus (HPV) infection. Symptomatic genital warts are seen in at least 1% of the age group of 15 - 49 years [<xref ref-type="bibr" rid="scirp.85896-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.85896-ref2">2</xref>] with about 50% or less being infected with HPV at some point in their lifetime [<xref ref-type="bibr" rid="scirp.85896-ref3">3</xref>] .</p><p>Genital warts have psychological and physical impacts on patients. Despite that warts are often asymptomatic; at sometimes they can cause itching, burning, pain, irritation, or bleeding especially during sexual activity [<xref ref-type="bibr" rid="scirp.85896-ref3">3</xref>] .</p><p>According to the 2012 European guideline for the management of anogenital warts, the treatment for CA range from self-application of topical agents like podophyllotoxin (0.15% cream or 0.5% solution) and imiquimod (5% cream) to clinic-based therapies like cryotherapy, trichloroacetic acid, electrosurgery, scissors excision, curettage or laser therapy. Formal surgery is reserved for large warts. There is no evidence that one type of therapy is significantly superior to another one or even appropriate for all types of warts. The data confirms that only surgical therapies have primary clearance rate approaching 100% and that recurrence occurs after all treatments with a rate of 20% - 30% or more. All therapies are associated with local skin reactions including itching, burning, erosions, and pain [<xref ref-type="bibr" rid="scirp.85896-ref4">4</xref>] .</p><p>To the best of our knowledge, there is only one published research study that studied the effect of adding podophyllin cautery to surgical excision for the eradication of vulvar CA. Thus, the rationale which intended for this parallel randomized controlled study was to test the hypothesis that adding podophyllin cautery to surgical excision will decrease the recurrence rate of CA more than surgical removal only.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Study Design</title><p>This controlled, randomized, and parallel trial was conducted in Cairo University Hospital and two private centers, Cairo, Egypt during the period January 2017 to March 2018. The study conformed to the Declaration of Helsinki principles and following the Medical Research Involving Human Subjects Act. The Bio-Medical Research Ethics Committee approved it at Cairo University. The purpose of the study was explained in simple and lay Arabic language to all women before their enrollment to the study, and an informed consent form was signed by and obtained from all those enrolled.</p><p>Women meeting all of the following criteria were considered for enrollment: aged 20 - 40 years, normal BMI, sexually active, married with vulvar condylomata accuminata coming to the centers during the period of the study.</p><p>Women presenting with any of the following were excluded from the study: previous history of infection with HPV, current history of other sexually transmitted diseases or pregnancy.</p></sec><sec id="s2_2"><title>2.2. Randomization and Blinding</title><p>Before the trial, computer-generated randomization schedules were generated and placed in sequentially numbered sealed opaque envelopes.</p><p>Block randomization with a block size of 4was used with 1:1 ratio of both groups (study and control groups). Recruitment was made before revealing the allocation. Sealed opaque envelope method was used for the allocation. The allocation was blind to both recruiter and participant.</p></sec><sec id="s2_3"><title>2.3. Interventions in Both Groups</title><p>The two groups were subjected to the same preparation. For all women in both the study and the control groups, surgical excision of the wart with scalpel was made. During the follow-up period (12 weeks) podophyllin cautery with podophyllin 0.5% solutionwas made once per week only for the study group only (30 women). All women were followed up every week for the entire follow-up period.</p></sec><sec id="s2_4"><title>2.4. Procedures</title><p>All women were subjected to detailed history (gyencologic, medical, and surgical), complete general examination to exclude the presence of any disorders. Gynecologic examinations were made systematically according to the centre’s protocol.</p><p>All surgeries were done under local anaesthesia. All women were followed up postoperatively for 24-hours then dismissed.</p></sec><sec id="s2_5"><title>2.5. Outcome Measures</title><p>The primary outcome measure was the incidence of recurrence of the lesion in both groups during the follow-up period. The secondary outcome measure was the incidence of side effects the follow-up period.</p></sec><sec id="s2_6"><title>2.6. Statistical Analysis</title><p>Sample size calculation suggested that a minimum of 28 subjects per group is required to detect 12% difference in incidence of postoperative bleeding between groups with a standard deviation of 1.56% (taking type I or α error of 5%, type II or β error of 20%). The 12% difference was based on a pilot study on 20 participants, 10 in each group. We decided to include 30 patients per group to allow for dropouts.</p><p>All statistical analyses were made by the intention to treat analysis method. All statistical tests were made using a significance level of 95%. P-value &lt; 0.05 was considered statistically significant. SPSS software (version 20.0, SSPS Inc., Chicago, IL, USA) was used for the statistical analyses. Data were presented as (mean &#177; SD) for continuous variables and as frequency and percent for categorical variables. Comparisons between groups were made using Chi-square test for categorical variable and the independent t-test for the continuous variables. For the analysis of the primary outcome variable, we calculated the relative risk (RR) with 95% confidence interval, the absolute risk reduction (ARR), the relative risk reduction (RRR) and the number needed to treat (NNT).</p></sec></sec><sec id="s3"><title>3. Results</title><p>Ninety-five (95) women with CA who came to the centers were asked to participate in the study. Eight women declined to participate, and 27 women did not meet the inclusion criteria (10 due to pregnancy and 17 were out of the age range), leaving 60 eligible for randomization with 30assigned to each group. One woman lost follow up and excluded from the per-protocol analysis. The dispositions of these women are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p><sec id="s3_1"><title>3.1. Baseline Characteristics</title><p>Both the study and the control groups were comparable with regard their baseline characteristics. There was no statistically significant difference (p &gt; 0.05) between the two groups regarding the age and BMI, as shown in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Patients’ characteristics</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Study group N = 30</th><th align="center" valign="middle" >Control group N = 30</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle" >Age in years</td><td align="center" valign="middle" >29.60 (6.17)</td><td align="center" valign="middle" >29.60 (6.17)</td><td align="center" valign="middle" >0.976</td></tr><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >22.00 (1.37)</td><td align="center" valign="middle" >21.62 (1.36)</td><td align="center" valign="middle" >0.289</td></tr></tbody></table></table-wrap></sec><sec id="s3_2"><title>3.2. Study Outcomes</title><p>During the follow-up period, 19 cases (65.5%) of the study group experienced pain versus only eight cases (26.7%) in the control group (p = 0.003). However, the development of scars was less in the study group 7 (24.1%) than in the control group 19 (63.3%), (p = 0.002).</p><p>Recurrence of the lesion was significantly lower (p = 0.001) in the study group than the control group. In the study group, five cases (17.2%) have recurrence whereas, in the control group, 18 (60.0%) had suffered recurrence. The ARR was 42.8% (CI 95%: 18% - 60.9%) with RR of 0.29% (CI 95%: 0.12% - 0.67%) and number needed to treat (NNT) 2% (CI 95%: 6% - 2%), as shown in <xref ref-type="table" rid="table2">Table 2</xref>.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>Because of the high rate of recurrence of CA after any modality of treatment (20% - 30% or more) [<xref ref-type="bibr" rid="scirp.85896-ref4">4</xref>] , researchers have to seek for more methods or combination of methods to reduce this high rate. This randomized controlled study was conducted to test the hypothesis that adding podophyllin cautery to surgical excision will decrease the recurrence rate of CA more than surgical removal only in cases with CA.</p><p>It was quite evident from this study that adding podophyllin cautery to surgical excision will further reduce the recurrence rate of CA where the ARR was 42.8% (CI 95%: 18% - 60.9%) with RR of 0.29% (CI 95%: 0.12% - 0.67%) and NNT 2% (CI 95%: 6% - 2%). Furthermore, the development of scars was lower in the study group than in the control group. However, during the follow-up period, pain was experienced more in the study group than in the control group.</p><p>According to the results of randomized clinical trials, data suggested that podophyllin resin is more effective than placebo and that, surgical treatments are largely equivalent [<xref ref-type="bibr" rid="scirp.85896-ref5">5</xref>] .</p><p>The antimitotic agent, podophyllin resin, one of the oldest nonsurgical treatments available for CA, destroys warts by inducing tissue necrosis locally. It is used compounded as a 10% - 25% suspension in tincture benzoin [<xref ref-type="bibr" rid="scirp.85896-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.85896-ref7">7</xref>] .</p><p>The extensive evaluation of efficacy [<xref ref-type="bibr" rid="scirp.85896-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.85896-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.85896-ref7">7</xref>] and safety of podophyllin resin showed that despite its efficacy, a variety of adverse effects including suppression of bone marrow, liver cell dysfunction, neuropsychological symptoms and gastrointestinal disturbance, and acute abdominal pain have been reported [<xref ref-type="bibr" rid="scirp.85896-ref8">8</xref>] - [<xref ref-type="bibr" rid="scirp.85896-ref20">20</xref>] . The recurrence rate after using podophyllin alone has been reported to be 65% of cases [<xref ref-type="bibr" rid="scirp.85896-ref21">21</xref>] - [<xref ref-type="bibr" rid="scirp.85896-ref26">26</xref>] . Due to the availability of a large number of alternative modalities of treatment and these reports of side effects, some European</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Treatment outcome</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Study group N = 29</th><th align="center" valign="middle" >Control group N = 30</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle" >Pain</td><td align="center" valign="middle" >19 (65.5%)</td><td align="center" valign="middle" >8 (26.7%)</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >Scar</td><td align="center" valign="middle" >7 (24.1%)</td><td align="center" valign="middle" >19 (63.3%)</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >Recurrence</td><td align="center" valign="middle" >5 (17.2%)</td><td align="center" valign="middle" >18 (60.0%)</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >Relative risk (RR)</td><td align="center" valign="middle"  colspan="3"  >0.29 (0.12 to 0.67)</td></tr><tr><td align="center" valign="middle" >Relative risk reduction (RRR)</td><td align="center" valign="middle"  colspan="3"  >71% (32.8% - 87.7%)</td></tr><tr><td align="center" valign="middle" >Absolute risk reduction (ARR)</td><td align="center" valign="middle"  colspan="3"  >42.8% (18% - 60.9%)</td></tr><tr><td align="center" valign="middle" >Number needed to treat (NNT)</td><td align="center" valign="middle"  colspan="3"  >2 (6 - 2)</td></tr></tbody></table></table-wrap><p>experts recommended against its use in the primary-care settings especially in large dose over an extensive area of skin surfaces which favored systemic absorption [<xref ref-type="bibr" rid="scirp.85896-ref8">8</xref>] . In the current study, we used podophyllin in lower frequency to avoid the adverse events.</p><p>Surgical removal by scalpel directly removes wart-affected tissues. Clinical research studies reported that 35% - 100% of cases showed clearance of visible warts immediately with recurrence rate of 19% - 29% one year after excision [<xref ref-type="bibr" rid="scirp.85896-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.85896-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.85896-ref28">28</xref>] . Podophyllin alone appears to be less effective than surgical excision [<xref ref-type="bibr" rid="scirp.85896-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.85896-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.85896-ref29">29</xref>] .</p><p>The evidence of the current study is fairly strong to prove that adding podophyllin cautery to surgical excision will decrease the recurrence rate of CA more than surgical removal only in cases with CA. Also, adding podophyllin cautery to surgical excision is safe.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Podophyllin cautery, when added to surgical removal, is effective in decreasing the incidence recurrence in cases with CA. Also, this combination is safe for those cases on the long run.</p></sec><sec id="s6"><title>Compliance with Ethical Standards</title>Declaration of Interest<p>All authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.</p>Ethical Approval<p>All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research bioethical committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p>Informed Consent<p>Informed consent was obtained from all individual participants included in the study.</p></sec><sec id="s7"><title>Declaration of Conflict of Interests</title><p>All authors have no things to disclose.</p></sec><sec id="s8"><title>Funding</title><p>This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.</p></sec><sec id="s9"><title>Acknowledgements</title><p>We would like to acknowledge Dr. Emad R.H. Issak (ClinAmygate) for his efforts in statistical analysis and editing of this manuscript.</p></sec><sec id="s10"><title>Cite this paper</title><p>Soliman, H.O. and Lashin, Y. (2018) The Efficacy of Podophyllin Cautery Added to Surgical Excision for Eradication of Vulvar Condylomata Accuminata; Randomized Controlled Trial. Journal of Cancer Therapy, 9, 559-567. https://doi.org/10.4236/jct.2018.97047</p></sec></body><back><ref-list><title>References</title><ref id="scirp.85896-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Gall, S.A. (2001) Female Genital Warts: Global Trends and Treatments. Infectious Diseases in Obstetrics and Gynecology, 9, 149-154.  
https://doi.org/10.1155/S1064744901000278</mixed-citation></ref><ref id="scirp.85896-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Money, D.M. and Roy, M. (2007) Canadian Consensus Guidelines on Human Papillomavirus. Journal of Obstetrics and Gynaecology Canada, 29, S1-S56.  
https://doi.org/10.1016/S1701-2163(16)32573-7</mixed-citation></ref><ref id="scirp.85896-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Workowski, K.A. and Berman, S. (2010) Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. MMWR Recommendations and Reports, 59, 1-110.</mixed-citation></ref><ref id="scirp.85896-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Lacey, C., Woodhall, S., Wikstrom, A. and Ross, J. (2013) 2012 European Guideline for the Management of Anogenital Warts. Journal of the European Academy of Dermatology and Venereology, 27, e263-e270.  
https://doi.org/10.1111/j.1468-3083.2012.04493.x</mixed-citation></ref><ref id="scirp.85896-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wiley, D.J. and Beutner, K.R. (2000) Genital Warts. Clinical Evidence, 3, 764-774.</mixed-citation></ref><ref id="scirp.85896-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Beutner, K.R., Wiley, D.J., Douglas, J.M., Tyring, S.K., Fife, K., Trofatter, K. and Stone, K.M. (1999) Genital Warts and Their Treatment. Clinical Infectious Diseases, 28, S37-S56. https://doi.org/10.1086/514722</mixed-citation></ref><ref id="scirp.85896-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Beutner, K.R., Richwald, G.A., Wiley, D.J., Reitano, M.V. and AMA Expert Panel on External Genital Warts (1998) External Genital Warts: Report of the American Medical Association Consensus Conference. Clinical Infectious Diseases, 27, 796-806. https://doi.org/10.1086/514964</mixed-citation></ref><ref id="scirp.85896-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">von Krogh, G., Lacey, C.J., Gross, G., Barrasso, R. and Schneider, A. (2000) European Course on HPV Associated Pathology: Guidelines for Primary Care Physicians for the Diagnosis and Management of Anogenital Warts. Sexually Transmitted Infections, 76, 162-168. https://doi.org/10.1136/sti.76.3.162</mixed-citation></ref><ref id="scirp.85896-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cassidy, D.E., Drewry, J. and Fanning, J.P. (1982) Podophyllum Toxicity: A Report of a Fatal Case and a Review of the Literature. Journal of Toxicology: Clinical Toxicology, 19, 35-44. https://doi.org/10.3109/15563658208990364</mixed-citation></ref><ref id="scirp.85896-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Tyring, S.K., Arany, I., Stanley, M.A., et al. (1998) A Randomized, Controlled, Molecular Study of Condylomata Acuminata Clearance during Treatment with Imiquimod. The Journal of Infectious Diseases, 178, 551-555.  
https://doi.org/10.1086/517472</mixed-citation></ref><ref id="scirp.85896-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Leslie, K.O. and Shitamoto, B. (1982) The Bone Marrow in Systemic Podophyllin Toxicity. American Journal of Clinical Pathology, 77, 478-480.  
https://doi.org/10.1093/ajcp/77.4.478</mixed-citation></ref><ref id="scirp.85896-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Filley, C.M., Graff-Richard, N.R., Lacy, J.R., Heitner, M.A. and Earnest, M.P. (1982) Neurologic Manifestations of Podophyllin Toxicity. Neurology, 32, 308-311.  
https://doi.org/10.1212/WNL.32.3.308</mixed-citation></ref><ref id="scirp.85896-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Boillot, A., Cordier, A., Guerault, E., et al. (1989) A Rare Case of Severe Toxic Peripheral Neuropathy: Poisoning by Podophyllin. Apropos of 1 Case. Journal de Toxicologie Clinique et Experimentale, 9, 409-412.</mixed-citation></ref><ref id="scirp.85896-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Gorin, F., Kindall, D. and Seyal, M. (1989) Dorsal Radiculopathy Resulting from Podophyllin Toxicity. Neurology, 39, 607-608.  
https://doi.org/10.1212/WNL.39.4.607</mixed-citation></ref><ref id="scirp.85896-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yang, C.M., Deng, J.F., Chen, C.F. and Chang, L.W. (1994) Experimental Podophyllotoxin (Bajiaolian) Poisoning: III. Biochemical Bases for Toxic Effects. Biomedical and Environmental Sciences, 7, 259-265.</mixed-citation></ref><ref id="scirp.85896-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kao, W.F., Hung, D.Z., Tsai, W.J., Lin, K.P. and Deng, J.F. (1992) Podophyllotoxin Intoxication: Toxic Effect of Bajiaolian in Herbal Therapeutics. Human &amp; Experimental Toxicology, 11, 480-487. https://doi.org/10.1177/096032719201100607</mixed-citation></ref><ref id="scirp.85896-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Tomczak, R.L. and Hake, D.H. (1992) Near Fatal Systemic Toxicity from Local Injection of Podophyllin for Pedal Verrucae Treatment. The Journal of Foot Surgery, 31, 36-42.</mixed-citation></ref><ref id="scirp.85896-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Chan, Y.W. (1991) Magnetic Resonance Imaging in Toxic Encephalopathy Due to Podophyllin Poisoning. Neuroradiology, 33, 372-373.  
https://doi.org/10.1007/BF00587830</mixed-citation></ref><ref id="scirp.85896-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Conard, P.F., Hanna, N., Rosenblum, M. and Gross, J.B. (1990) Delayed Recognition of Podophyllum Toxicity in a Patient Receiving Epidural Morphine. Anesthesia &amp; Analgesia, 71, 191-193. https://doi.org/10.1213/00000539-199008000-00013</mixed-citation></ref><ref id="scirp.85896-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Oliveira, A.S., Calia, L.C., Kiyomoto, B.H., Povoa, E.F., Schmidt, B. and Gabbai, A.A. (1996) Acute Necrotizing Myopathy and Podophyllin Toxicity: Report of a Fatal Case. Arquivos de Neuro-Psiquiatria, 54, 288-292.  
https://doi.org/10.1590/S0004-282X1996000200017</mixed-citation></ref><ref id="scirp.85896-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Douglas, J.M., Eron, L.J., Judson, F.N., et al. (1990) A Randomized Trial of Combination Therapy with Intralesional Interferon α 2b and Podophyllin versus Podophyllin Alone for the Therapy of Anogenital Warts. The Journal of Infectious Diseases, 162, 52-59. https://doi.org/10.1093/infdis/162.1.52</mixed-citation></ref><ref id="scirp.85896-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Edwards, A., Atma-Ram, A. and Thin, R.N. (1988) Podophyllotoxin 0.5% v Podophyllin 20% to Treat Penile Warts. Genitourinary Medicine, 64, 263-265.  
https://doi.org/10.1136/sti.64.4.263</mixed-citation></ref><ref id="scirp.85896-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Gabriel, G. and Thin, R.N. (1983) Treatment of Anogenital Warts. Comparison of Trichloracetic Acid and Podophyllin versus Podophyllin Alone. The British Journal of Venereal Diseases, 59, 124-126. https://doi.org/10.1136/sti.59.2.124</mixed-citation></ref><ref id="scirp.85896-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Hellberg, D., Svarrer, T., Nilsson, S. and Valentin, J. (1995) Self-Treatment of Female External Genital Warts with 0.5% Podophyllotoxin Cream (Condyline) vs. Weekly Applications of 20% Podophyllin Solution. International Journal of STD &amp; AIDS, 6, 257-261. https://doi.org/10.1177/095646249500600407</mixed-citation></ref><ref id="scirp.85896-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Kinghorn, G.R., McMillan, A., Mulcahy, F., Drake, S., Lacey, C. and Bingham, J.S. (1993) An Open, Comparative, Study of the Efficacy of 0.5% Podophyllotoxin Lotion and 25% Podophyllotoxin Solution in the Treatment of Condylomataacuminata in Males and Females. International Journal of STD &amp; AIDS, 4, 194-199.  
https://doi.org/10.1177/095646249300400403</mixed-citation></ref><ref id="scirp.85896-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Lassus, A., Haukka, K. and Forsstrom, S. (1984) Podophyllotoxin for Treatment of Genital Warts in Males: A Comparison with Conventional Podophyllin Therapy. European Journal of Sexually Transmitted Diseases, 2, 31-33.</mixed-citation></ref><ref id="scirp.85896-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Jensen, S.L. (1985) Comparison of Podophyllin Application with Simple Surgical Excision in Clearance and Recurrence of Perianal Condylomataacuminata. The Lancet, 2, 1146-1148. https://doi.org/10.1016/S0140-6736(85)92677-7</mixed-citation></ref><ref id="scirp.85896-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Khawaja, H.T. (1989) Podophyllin versus Scissor Excision in the Treatment of Perianal Condylomataacuminata: A Prospective Study. British Journal of Surgery, 76, 1067-1068. https://doi.org/10.1002/bjs.1800761027</mixed-citation></ref><ref id="scirp.85896-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Duus, B.R., Philipsen, T., Christensen, J.D., Lundvall, F. and Sondergaard, J. (1985) Refractory Condylomataacuminata: A Controlled Clinical Trial of Carbon Dioxide Laser versus Conventional Surgical Treatment. Genitourinary Medicine, 61, 59-61.</mixed-citation></ref></ref-list></back></article>